Monte Rosa Therapeutics (GLUE) Short Interest Ratio & Short Volume $4.91 +0.12 (+2.51%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Monte Rosa Therapeutics Short Interest DataMonte Rosa Therapeutics (GLUE) has a short interest of 7.53 million shares, representing 16.37% of the float (the number of shares available for trading by the public). This marks a 39.19% increase in short interest from the previous month. The short interest ratio (days to cover) is 10.4, indicating that it would take 10.4 days of the average trading volume of 1.05 million shares to cover all short positions.Current Short Interest7,530,000 sharesPrevious Short Interest5,410,000 sharesChange Vs. Previous Month+39.19%Dollar Volume Sold Short$33.36 millionShort Interest Ratio10.4 Days to CoverLast Record DateApril 15, 2025Outstanding Shares61,510,000 sharesFloat Size45,990,000 sharesShort Percent of Float16.37%Today's Trading Volume340,790 sharesAverage Trading Volume1,050,881 sharesToday's Volume Vs. Average32% Short Selling Monte Rosa Therapeutics? Sign up to receive the latest short interest report for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGLUE Short Interest Over TimeGLUE Days to Cover Over TimeGLUE Percentage of Float Shorted Over Time Monte Rosa Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20257,530,000 shares $33.36 million +39.2%16.4%10.4 $4.43 3/31/20255,410,000 shares $25.10 million -23.0%11.8%6.9 $4.64 3/15/20257,030,000 shares $44.08 million -12.6%15.3%8.7 $6.27 2/28/20258,040,000 shares $44.22 million +0.1%17.5%8.2 $5.50 2/15/20258,030,000 shares $54.44 million -0.5%17.5%7.6 $6.78 1/31/20258,070,000 shares $53.75 million -7.9%17.6%7 $6.66 1/15/20258,760,000 shares $54.66 million -4.2%19.1%3.2 $6.24 12/31/20249,140,000 shares $63.43 million +8.8%19.9%3.3 $6.94 12/15/20248,400,000 shares $63.50 million -24.0%18.2%3.2 $7.56 11/30/202411,050,000 shares $114.48 million -0.9%23.9%4.5 $10.36 Get the Latest News and Ratings for GLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202411,150,000 shares $86.30 million +42.2%24.1%5.1 $7.74 10/31/20247,840,000 shares $66.64 million +49.9%17.0%3.8 $8.50 10/15/20245,230,000 shares $26.78 million +19.4%11.7%15 $5.12 9/30/20244,380,000 shares $23.21 million +33.9%9.8%12.2 $5.30 9/15/20243,270,000 shares $19.88 million +6.9%7.5%11.7 $6.08 8/31/20243,060,000 shares $18.88 million +9.7%7.2%12.9 $6.17 8/15/20242,790,000 shares $13.67 million +0.4%6.5%11.9 $4.90 7/31/20242,780,000 shares $12.57 million -2.8%6.5%11.2 $4.52 7/15/20242,860,000 shares $11.98 million +11.7%6.7%12.2 $4.19 6/30/20242,560,000 shares $9.57 million +29.3%6.0%11.8 $3.74 6/15/20241,980,000 shares $7.58 million +3.7%4.6%9.9 $3.83 5/31/20241,910,000 shares $7.87 million -17.3%5.0%10.3 $4.12 5/15/20242,310,000 shares $12.08 million +20.9%6.0%13.8 $5.23 4/30/20241,910,000 shares $10.16 million +2.1%6.0%13.7 $5.32 4/15/20241,870,000 shares $12.29 million +11.3%5.9%14.2 $6.57 3/31/20241,680,000 shares $11.84 million -8.2%5.3%11.2 $7.05 3/15/20241,830,000 shares $11.73 million -0.5%5.8%11.2 $6.41 2/29/20241,840,000 shares $11.65 million -7.1%5.8%9.6 $6.33 2/15/20241,980,000 shares $10.95 million +3.7%6.3%9.6 $5.53 1/31/20241,910,000 shares $10.12 million -2.6%6.1%9.1 $5.30 1/15/20241,960,000 shares $11.76 million -4.9%6.2%8 $6.00 12/31/20232,060,000 shares $11.64 million -12.7%6.5%6.6 $5.65 12/15/20232,360,000 shares $11.80 million -20.5%7.5%7.7 $5.00 11/30/20232,970,000 shares $9.21 million -2.9%9.4%10.7 $3.10 11/15/20233,060,000 shares $11.26 million -8.7%9.7%12.1 $3.68 10/31/20233,350,000 shares $11.39 million -10.2%10.8%12.4 $3.40 10/15/20233,730,000 shares $18.02 million -6.8%12.1%15.6 $4.83 9/30/20234,000,000 shares $19.16 million +4.4%12.9%25.8 $4.79 9/15/20233,830,000 shares $23.02 million +7.9%12.4%25.8 $6.01 8/31/20233,550,000 shares $20.84 million +14.2%11.5%23.3 $5.87M.A.G.A. is Finished – This Could be even Better (Ad)You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).When you see what could happen – I think you’ll be excited. 8/15/20233,110,000 shares $20.46 million +11.1%10.0%19 $6.58 7/31/20232,800,000 shares $19.80 million +6.5%7.0%19.3 $7.07 7/15/20232,630,000 shares $18.33 million +1.9%6.6%14.1 $6.97 6/30/20232,580,000 shares $17.67 million +5.7%6.5%12.3 $6.85 6/15/20232,440,000 shares $18.03 million +6.6%6.1%11.9 $7.39 5/31/20232,290,000 shares $16.90 million No Change5.8%12 $7.38 5/15/20232,290,000 shares $13.40 million +2.2%5.8%13.5 $5.85 4/30/20232,240,000 shares $10.17 million -10.0%5.6%13.5 $4.54 4/15/20232,490,000 shares $17.06 million +2.9%6.3%16.5 $6.85 3/31/20232,420,000 shares $18.85 million +9.0%6.1%17.2 $7.79 3/15/20232,220,000 shares $14.50 million -3.1%5.6%15.9 $6.53 2/28/20232,290,000 shares $13.92 million -8.0%5.9%15.8 $6.08 2/15/20232,490,000 shares $16.98 million -33.2%6.4%17.1 $6.82 1/31/20233,730,000 shares $27.60 million -0.8%9.6%22.6 $7.40 1/15/20233,760,000 shares $29.37 million -13.4%9.7%25.9 $7.81 12/30/20224,340,000 shares $33.03 million +1.4%11.2%27.7 $7.61 12/15/20224,280,000 shares $40.57 million -1.8%11.1%24 $9.48 11/30/20224,360,000 shares $36.97 million -6.6%14.6%20.1 $8.48 11/15/20224,670,000 shares $43.99 million -4.3%15.7%20.7 $9.42 10/31/20224,880,000 shares $44.90 million +1.2%16.4%21.3 $9.20 10/15/20224,820,000 shares $37.45 million -6.2%16.2%21.3 $7.77 9/30/20225,140,000 shares $41.99 million +4.5%17.3%23 $8.17 9/15/20224,920,000 shares $39.26 million -3.3%16.6%24.2 $7.98 8/31/20225,090,000 shares $40.31 million +6.5%17.2%26.3 $7.92 8/15/20224,780,000 shares $47.51 million +3.5%16.1%23.4 $9.94 7/31/20224,620,000 shares $41.90 million No Change15.6%23.8 $9.07 7/15/20224,620,000 shares $47.36 million -0.9%15.6%23.8 $10.25 6/30/20224,660,000 shares $45.06 million -5.5%15.7%23.2 $9.67 6/15/20224,930,000 shares $37.76 million -13.7%16.6%23.6 $7.66 5/31/20225,710,000 shares $44.20 million +1.1%19.3%22.2 $7.74 5/15/20225,650,000 shares $46.27 million -0.2%19.1%21 $8.19 4/30/20225,660,000 shares $61.69 million -1.9%19.1%20.4 $10.90 4/15/20225,770,000 shares $78.88 million -3.4%19.5%18.9 $13.67 3/31/20225,970,000 shares $83.70 million +10.8%N/A18.9 $14.02 3/15/20225,390,000 shares $75.24 million +8.0%18.3%17.1 $13.96 2/28/20224,990,000 shares $71.56 million +10.9%16.9%21.1 $14.34 2/15/20224,500,000 shares $65.16 million +32.0%15.3%20.1 $14.48 1/31/20223,410,000 shares $43.17 million -3.1%11.6%17 $12.66 1/15/20223,520,000 shares $52.80 million +5.4%N/A21 $15.00 12/31/20213,340,000 shares $68.20 million +3.4%11.3%22.7 $20.42 12/15/20213,230,000 shares $59.79 million +17.0%11.0%23.4 $18.51 11/30/20212,760,000 shares $53.52 million +9.1%9.4%15.8 $19.39 11/15/20212,530,000 shares $58.19 million -0.4%8.6%13.7 $23.00 10/29/20212,540,000 shares $59.56 million +5.8%9.3%12.8 $23.45 10/15/20212,400,000 shares $50.88 million -5.1%8.8%11.5 $21.20 9/30/20212,530,000 shares $56.37 million +30.4%9.3%11.2 $22.28 9/15/20211,940,000 shares $62.82 million +12.8%7.1%6.1 $32.38 8/31/20211,720,000 shares $61.39 million +44.5%6.5%5.8 $35.69 8/13/20211,190,000 shares $40.25 million No Change5.9%3.8 $33.82 GLUE Short Interest - Frequently Asked Questions What is Monte Rosa Therapeutics' current short interest? Short interest is the volume of Monte Rosa Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 7,530,000 shares of GLUE short. 16.37% of Monte Rosa Therapeutics' shares are currently sold short. Learn More on Monte Rosa Therapeutics' current short interest. What is a good short interest ratio for Monte Rosa Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GLUE shares currently have a short interest ratio of 10.0. Learn More on Monte Rosa Therapeutics's short interest ratio. Which institutional investors are shorting Monte Rosa Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Monte Rosa Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Monte Rosa Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.37% of Monte Rosa Therapeutics' floating shares are currently sold short. Is Monte Rosa Therapeutics' short interest increasing or decreasing? Monte Rosa Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 7,530,000 shares, an increase of 39.2% from the previous total of 5,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Monte Rosa Therapeutics' float size? Monte Rosa Therapeutics currently has issued a total of 61,510,000 shares. Some of Monte Rosa Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Monte Rosa Therapeutics currently has a public float of 45,990,000 shares. How does Monte Rosa Therapeutics' short interest compare to its competitors? 16.37% of Monte Rosa Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Monte Rosa Therapeutics: Iovance Biotherapeutics, Inc. (26.88%), Amphastar Pharmaceuticals, Inc. (8.47%), Syndax Pharmaceuticals, Inc. (25.86%), Adaptive Biotechnologies Co. (7.14%), Aurinia Pharmaceuticals Inc. (9.00%), 89bio, Inc. (16.51%), Wave Life Sciences Ltd. (10.79%), X4 Pharmaceuticals, Inc. (5.24%), Enliven Therapeutics, Inc. (23.47%), Collegium Pharmaceutical, Inc. (14.46%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Monte Rosa Therapeutics stock? Short selling GLUE is an investing strategy that aims to generate trading profit from Monte Rosa Therapeutics as its price is falling. GLUE shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Monte Rosa Therapeutics? A short squeeze for Monte Rosa Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GLUE, which in turn drives the price of the stock up even further. How often is Monte Rosa Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GLUE, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies IOVA Short Squeeze AMPH Short Squeeze SNDX Short Squeeze ADPT Short Squeeze AUPH Short Squeeze ETNB Short Squeeze WVE Short Squeeze XFOR Short Squeeze ELVN Short Squeeze COLL Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GLUE) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
